October 24, 2019 - Data from a phase 1, open-label, multi-center safety trial of lyophilized platelets were recently presented at the 2019 AABB Annual Meeting in San Antonio, Texas. Thrombosomes® (lyophilized platelets) are prepared from a pool of apheresis-derived human platelet units, pathogen-reduced with heat sterilization, and freeze-dried in the presence of trehalose (a naturally-derived simple sugar) and other small molecules which stabilize their structure until reconstruction.
-
About this Post
- Title: Transfusion News – Thrombosomes (Lyophilized Platelets) Appear Safe in Phase 1 Trial
- Posted: November 5th, 2019
- Author: Rob Woods
- Filed Under: Uncategorized
-
Recent Posts
- Cellphire President G. Michael Fitzpatrick Awarded Armed Services Program Lifetime Achievement Award
- Cellphire Subsidiary, BodeVet, Inc., Awarded $1.7 Million U.S. Army Contract
- Cellphire Announces Orphan Drug Designation of Thrombosomes® for Treatment of Acute Radiation Syndrome
- Cellphire Announces Exercise by BARDA of Option 3 of Contract to Develop Platelet-Based Hemostatic
- Cellphire Begins Phase 2 Trial of Thrombosomes® in Bleeding Thrombocytopenic Patients
-
Categories
- No categories
-
Archives